Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
In the Summary of Product Characteristics, the SELECT results report: 569 of 8,803 people in the semaglutide group had a primary cardiovascular endpoint event 701 of 8,801 people in the placebo group had a primary cardiovascular endpoint event the hazard ratio was 0.80 with a 95% confidence interval of 0.72 to 0.90 This means semaglutide reduced the relative risk of the composite cardiovascular outcome by about 20% compared with placebo in this trial population
Berberine: Natures Ozempic
doi: 10.1016/j.bbamcr.2023.119573 7 BentS.LawtonB.WarrenT.WidjajaF.DangK.FaheyJ
These trends underscore a growing awareness and demand for natural ingredients that offer targeted health benefits, as well as a need to further the education around supplementation
